The companies also signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions. Both plan to offer a range of IV solutions in the U.S. beginning in 2016. Financial and contract terms were not disclosed.
The NC plant employs 100 people and features advanced pharmaceutical manufacturing and packaging technologies, which was approved by the FDA in 2012. It currently produces seven drugs in ready-to-administer prefilled syringes and has capacity for future growth. Fresenius plans to further invest in the facility to make it a global center of excellence for prefilled syringe production.
“Ready-to-administer, prefilled syringes are a growing segment in health care due to increased focus on medication safety and labor-saving efficiency,” said John Ducker, president and chief executive officer of Fresenius Kabi USA. “They are a natural complement to our portfolio, enabling us to offer customers more choices and a broader range of specialty injectable medicines in vials as well as ready-to-administer presentations.”
“We believe Fresenius Kabi is a better owner for the BD Rx business, because it complements their existing capabilities in the injectable pharmaceutical industry,” said Tom Polen, president of BD’s Medical Segment. “In addition, we look forward to working with Fresenius Kabi to extend our medication management strategy through the addition of a portfolio of IV fluids, which will broaden our clinical and economical end-to-end solutions for our customers and their patients.”